| Jonathan JB Brauner, Md | |
| +32 02 555 34 27 ext 3427 | |
| [email protected] |
| Béatrice BG Gulbis, Phd MD | |
| +32 02 555 34 27 ext 3427 | |
| [email protected] |
1 Belgium site
> 17 Years
Observational
All
Genetic
Unknown
The objective of the study is to refine our knowledge on the physiopathology of the symptoms
and the complications for the patients affected by a drepanocytic syndrome.
The establishment of risk factors and indicators of severity will allow to target better the
patients requiring an adequate strategy in order to prevent the installation of some
complications or to limit their worsening.
– Patients 18 years or older with sickle cell syndrome
– Signing an inform consent form after validation on it by the Ethics Committees of the
participating centers.
– Any pathology concomitant risk of nephropathy
– Severe CVO within the month preceding the sampling
– Transfusions within 3 months prior to sampling
– Pregnant patient or within 3 months post- accouhcement